276 related articles for article (PubMed ID: 28009421)
1. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
5. Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer - acute toxicity of 12C for PC.
Nikoghosyan AV; Schulz-Ertner D; Herfarth K; Didinger B; Münter MW; Jensen AD; Jäkel O; Hoess A; Haberer T; Debus J
Acta Oncol; 2011 Aug; 50(6):784-90. PubMed ID: 21767175
[TBL] [Abstract][Full Text] [Related]
6. Functional imaging-guided carbon ion irradiation with simultaneous integrated boost for localized prostate cancer: study protocol for a phase II randomized controlled clinical trial.
Hu W; Li P; Hong Z; Guo X; Pei Y; Zhang Z; Zhang Q
Trials; 2022 Nov; 23(1):934. PubMed ID: 36348363
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.
Freedman GM; Meropol NJ; Sigurdson ER; Hoffman J; Callahan E; Price R; Cheng J; Cohen S; Lewis N; Watkins-Bruner D; Rogatko A; Konski A
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1389-93. PubMed ID: 17394942
[TBL] [Abstract][Full Text] [Related]
8. Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300).
Gugliandolo SG; Marvaso G; Comi S; Pepa M; Romanò C; Zerini D; Augugliaro M; Russo S; Vischioni B; Valvo F; Giandini T; Avuzzi B; Valdagni R; Ciardo D; De Cobelli O; Jereczek-Fossa BA; Cattani F; Orecchia R
Phys Med; 2020 Aug; 76():327-336. PubMed ID: 32750548
[TBL] [Abstract][Full Text] [Related]
9. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
[TBL] [Abstract][Full Text] [Related]
10. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
11. Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique.
Habl G; Hatiboglu G; Edler L; Uhl M; Krause S; Roethke M; Schlemmer HP; Hadaschik B; Debus J; Herfarth K
BMC Cancer; 2014 Mar; 14():202. PubMed ID: 24641841
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
13. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
14. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer.
Sanguineti G; Endres EJ; Parker BC; Bicquart C; Little M; Chen G; Berilgen J
Acta Oncol; 2008; 47(2):301-10. PubMed ID: 18210303
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
16. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
[TBL] [Abstract][Full Text] [Related]
18. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
[TBL] [Abstract][Full Text] [Related]
19. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions.
Okada T; Tsuji H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Tsujii H;
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):968-72. PubMed ID: 22898380
[TBL] [Abstract][Full Text] [Related]
20. High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach.
Marvaso G; Jereczek-Fossa BA; Riva G; Bassi C; Fodor C; Ciardo D; Cambria R; Pansini F; Zerini D; De Marco P; Cattani F; De Cobelli O; Orecchia R
Clin Genitourin Cancer; 2017 Jun; 15(3):376-383. PubMed ID: 28190704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
